Home > Healthcare > Pharmaceuticals > Finished Drug Form > Erythropoietin Drugs Market

Erythropoietin Drugs Market Share

Report ID: GMI10624
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Erythropoietin Drugs Market Share

The erythropoietin drugs sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. Key to market strategy is the consistent launch of innovative products, utilizing a range of technologies. Major industry leaders wield significant influence, spearheading progress with hefty investments in R&D. Furthermore, strategic partnerships and M&A activities play a crucial role in bolstering market standing and broadening global reach, especially in the face of changing regulations.

Erythropoietin Drugs Market Companies

Some of the eminent market participants operating in the erythropoietin drugs industry include:

AstraZeneca PLC
Amgen, Inc.
Biocon Limited
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
F. Hoffmann-La Roche Ltd.
Intas Pharmaceuticals Ltd.
Johnson & Johnson
Kyowa Kirin Co., Ltd.
LG Chem, Ltd.
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Erythropoietin drugs market size was valued at around USD 10.4 billion in 2023 and is estimated to grow at 4.5% CAGR from 2024 to 2032 owing to the rising prevalence of cancer.

The biosimilars segment in the market is forecast to reach USD 7 billion by 2032 as they are less expensive than their reference biologics, making healthcare more affordable.

The erythropoietin drugs market in the U.S. is projected to reach USD 5.8 billion by 2032 due to highly developed healthcare system with state-of-the-art medical facilities and advanced technology.

AstraZeneca PLC, Amgen, Inc., Biocon Limited, Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., and Intas Pharmaceuticals Ltd. among others.